8-K: Exicure Receives Nasdaq Delinquency Notice, Files Delayed 10-Q

Exicure, Inc. announced it received a Nasdaq delinquency notice for a delayed 10-Q filing due to personnel changes, but has since filed the report and believes it has regained compliance.

Summary

• Exicure, Inc. received a notification from Nasdaq on May 28, 2026, stating it was not in compliance with Listing Rule 5250(c)(1) due to a delayed filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
• The delay was attributed to additional time needed following changes in the company's financial reporting personnel and related filing procedures.
• The company filed its Form 10-Q for the period ended March 31, 2026, on May 29, 2026.
• Exicure believes it has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing the report.
• The company has historically been an early-stage biotechnology company focused on nucleic acid therapies and is now exploring strategic alternatives after a restructuring and suspension of clinical activities.
• In January 2025, Exicure acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases, with a lead program for stem cell mobilization.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it addresses a procedural issue (delayed filing) and its resolution, without providing new financial performance data or significant strategic updates beyond ongoing exploration of alternatives.

Positives

• The company has filed its delayed Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
• Exicure believes it has regained compliance with Nasdaq Listing Rule 5250(c)(1).
• The company is exploring strategic alternatives to maximize stockholder value.
• Exicure acquired a clinical-stage biotechnology company in January 2025 with a lead program for hematologic diseases.

Negatives

• The company received a notification from Nasdaq for non-compliance with listing rules due to a delayed filing.
• The delay in filing was caused by changes in financial reporting personnel and procedures.
• The company has undergone restructuring and suspended clinical and development activities.

Risks

• The company's actual results could differ from forward-looking statements due to risks and uncertainties.
• The company is subject to risks and uncertainties detailed in its Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings.

Future Outlook

The company is exploring strategic alternatives to maximize stockholder value. Forward-looking statements are subject to risks and uncertainties, and actual results may differ. The company undertakes no duty to update forward-looking statements except as required by law.

Management Comments

• Exicure believes that it has regained compliance with Nasdaq Listing Rule 5250(c)(1).
• The delay was primarily due to additional time required following changes in the Company's financial reporting personnel and related filing procedures.

Industry Context

StockSavvy.ai notes that Nasdaq compliance issues due to delayed filings, especially following personnel changes in financial reporting, are not uncommon in the biotechnology sector, which often experiences rapid growth and restructuring.

Management Changes

Stakeholder Impact

• Shareholders: Potential concern over Nasdaq compliance issues, but reassurance provided by the filing of the report and belief in regained compliance. Ongoing exploration of strategic alternatives may impact future value.
• Creditors: No immediate impact indicated, but continued compliance with listing rules is important for market perception.
• Employees: Potential impact from changes in financial reporting personnel and restructuring activities.

Next Steps

• Continue exploring strategic alternatives to maximize stockholder value.
• Monitor compliance with Nasdaq listing requirements.

Key Dates

Keywords

Exicure, 8-K, Nasdaq, Form 10-Q, Biotechnology, Financial Reporting, Compliance, Hematologic Diseases